“…However, the OFS remains a scale without formal measures of validity in any language until now, partly because maxillary cancer is a relatively rare tumour with high mortality [ 2 ]. In fact, the number of samples in these studies involved in measuring the reliability of OFS is within the range of 30–57 patients [ 7 , [12] , [13] , [14] , [15] ], not meeting the criterion with a minimum of five participants per scale item to evaluate the construct validity [ 16 ].…”